The company said Merger Sub merged with and into Paragon 28 on April 21, 2025, with Paragon 28 surviving as a wholly owned subsidiary of Zimmer, Inc.

1. 01

   The company said Merger Sub merged with and into Paragon 28 on April 21, 2025, with Paragon 28 surviving as a wholly owned subsidiary of Zimmer, Inc.

2. 02

   The company said each Paragon 28 common share was converted into the right to receive $13.00 in cash, without interest, and 1 contingent value right(s). The CVR entitles the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved.

3. 03

   The company said Paragon 28 shares stopped trading on the New York Stock Exchange before the market opened on April 21, 2025 following the merger's completion and will be delisted.

4. 04

   The company said the merger was carried out under the Agreement and Plan of Merger entered into on January 28, 2025. It described Paragon 28 as a medical device company focused exclusively on the foot and ankle orthopedic space.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.